US 11667911
Use of exonucleases to improve CRISPR/CAS-mediated genome editing
granted A61KA61K31/7105A61K38/465
Quick answer
US patent 11667911 (Use of exonucleases to improve CRISPR/CAS-mediated genome editing) held by Editas Medicine, Inc. expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Editas Medicine, Inc.
- Grant date
- Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 25
- CPC classes
- A61K, A61K31/7105, A61K38/465, A61K9/5123